Table 1.
Demographic and clinical characteristics
| N=36 | |
| Age, mean (SD) | 49.5 (12.2) |
| Sex, n (%) | |
| Female | 19 (52.8) |
| Male | 17 (47.2) |
| BMI, mean (SD) | 30.0 (8.5) |
| Smoking history, n (%) | |
| Current | 16 (44.4) |
| Ex-smoker | 8 (22.2) |
| Non-smoker | 12 (33.3) |
| Psoriasis type, n (%) | |
| Plaque | 32 (88.9) |
| Nail involvement | 5 (13.9) |
| Scalp involvement | 9 (25.0) |
| Pustular | 4 (11.1) |
| Inversa | 3 (8.3) |
| Duration of skin disease, years, mean (SD) | 16.7 (16.8) |
| Duration of arthralgia, months, mean (SD) | 3.8 (3.4) |
| Inflammatory arthralgia | 34 (94.6%) |
| Non-specific arthralgia | 2 (5.6%) |
| Family history (1st grade), n (%) | |
| Psoriasis | 12 (33.3) |
| Rheumatic disease | 3 (8.3) |
| Physical activity | |
| Sport | |
| Sedentary lifestyle | 20 (55.5%) |
| 1 hour or less weekly | 5 (13.9%) |
| 1–3.5 hours weekly | 5 (13.9%) |
| 3.5–7 hours weekly | 4 (11.1%) |
| More than 7 hours weekly | 2 (5.6%) |
| Occupational | |
| Sedentary work | 21 (58.3%) |
| Some physical activity | 6 (16.7%) |
| Physically demanding work | 9 (25.0%) |
| Disease activity | |
| C reactive protein, mg/dL, mean (SD) | 6.1 (1.9) |
| Pain VAS, mm, mean (SD) | 43 (22) |
| Tender joint count 68, median (IQR) | 1 (0–5) |
| Swollen joint count 66, median (IQR) | 0 (0–0) |
| LEI, median (IQR) | 0.0 (0.0–1.3) |
| MASES, median (IQR) | 0.0 (0.0–1.5) |
| HAQ, median (IQR) | 0.1 (0.0–0.6) |
| Treatment | |
| Topical therapies, n (%) | 25 (69.4) |
| Oral glucocorticoids, n (%) | 0 (0) |
| NSAIDs (occasional use), n (%) | 17 (47.2) |
| csDMARDs, n (%) | 0 (0) |
| bDMARDs, n (%) | 7 (19.5) |
| Ustekinumab | 4 (11.1) |
| Guselkumab | 1 (2.8) |
| Risankizumab | 1 (2.8) |
| Ixekizumab | 1 (2.8) |
bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; LEI, Leeds Enthesitis Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; NSAIDs, non-steroidal anti-inflammatory drugs; VAS, Visual Analogue Scale.